Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 153,988 | 307,584 | 197,538 | 290,875 | 383,794 |
| Marketable Securities | 444,333 | 432,612 | 539,579 | 554,881 | 581,614 |
| Receivables | 28,369 | 28,432 | 25,383 | 24,720 | 25,032 |
| Inventories | 17,809 | 16,231 | 15,191 | 15,083 | 12,462 |
| TOTAL | $707,519 | $856,604 | $846,884 | $949,492 | $1,070,936 |
| Non-Current Assets | |||||
| PPE Net | 177,073 | 141,247 | 119,069 | 104,568 | 87,570 |
| Investments And Advances | 241,122 | 293,858 | 290,458 | 231,741 | 216,380 |
| Intangibles | 204,398 | 175,194 | 175,275 | 175,356 | 175,437 |
| Other Non-Current Assets | 53,917 | 55,494 | 53,115 | 51,287 | 47,440 |
| TOTAL | $676,510 | $665,793 | $637,917 | $562,952 | $526,827 |
| Total Assets | $1,384,029 | $1,522,397 | $1,484,801 | $1,512,444 | $1,597,763 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 23,685 | 17,138 | 15,575 | 21,790 | 15,744 |
| Accrued Expenses | 126,356 | 145,555 | 109,660 | 91,060 | 82,699 |
| Other current liabilities | 5,867 | 7,609 | N/A | 3,912 | 19,221 |
| TOTAL | $167,231 | $181,368 | $135,933 | $127,067 | $127,044 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 387,068 | 385,162 | 381,888 | 379,900 | 382,831 |
| TOTAL | $420,374 | $418,468 | $415,194 | $413,206 | $416,137 |
| Total Liabilities | $587,605 | $599,836 | $551,127 | $540,273 | $543,181 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 69,930 | 69,385 | 68,162 | 67,836 | 67,483 |
| Common Shares | 70 | 69 | 68 | 68 | 67 |
| Retained earnings | -2,225,921 | -2,073,601 | -1,951,143 | -1,878,145 | -1,755,717 |
| Other shareholders' equity | -6,554 | -1,404 | 54 | 232 | 56 |
| TOTAL | $796,424 | $922,561 | $933,674 | $972,171 | $1,054,582 |
| Total Liabilities And Equity | $1,384,029 | $1,522,397 | $1,484,801 | $1,512,444 | $1,597,763 |